In the rapidly evolving world of cancer treatments, CAR-T cell therapy stands out for its effectiveness tackling hematologic tumors. Booming demand for such therapies powered Legend Biotech Corp. LEGN ...
PISCATAWAY, N.J., April 14, 2026 /PRNewswire/ -- GenScript Biotech Corporation today announced its 2025 Environmental, Social, and Governance (ESG) Report, positioning the company at the forefront of ...
SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation ...
Recent price moves and business snapshot Genscript Biotech (SEHK:1548) has seen the stock slip about 0.5% on the day and roughly 5.6% over the past week, while posting a gain of around 13% over the ...
NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, ...
R&D Innovation to Lead the Future, Deepening Customer Value Creation From the performance during the 2023 reporting period, GenScript Group's overall development is optimistic, with each business ...
(Reuters) -The U.S. House of Representatives committee on China on Tuesday sent a letter to the directors of the FBI and national intelligence, renewing its concerns about GenScript Biotechnology's ...
Earnings call GenScript's 2025 revenue surged 61.4% YoY to $959.5M, with adjusted net profit up 285% to $230.3M, fueled by strong segment performance and a major licensing deal. Despite a non-cash ...
Good day and thank you for standing by. Welcome to Genscript Biotech 2025 Interim Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, ...
Good day, and thank you for standing by. Welcome to GenScript Biotech Annual Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now ...
Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...
The share-price surge came as promising cancer trial data overshadowed continuing scrutiny of China's biotechnology sector by US lawmakers GenScript Biotech Holdings surged in Hong Kong after its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results